UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008771
Receipt number R000010308
Scientific Title Phase II study of pemetrexed or pemetrexed plus bevacizumab for previously untreated elderly non-squamous non-small cell lung cancer
Date of disclosure of the study information 2012/08/27
Last modified on 2021/02/15 10:55:11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II study of pemetrexed or pemetrexed plus bevacizumab for previously untreated elderly non-squamous non-small cell lung cancer

Acronym

Phase II trial of PEM or PEM/BEV

Scientific Title

Phase II study of pemetrexed or pemetrexed plus bevacizumab for previously untreated elderly non-squamous non-small cell lung cancer

Scientific Title:Acronym

Phase II trial of PEM or PEM/BEV

Region

Japan


Condition

Condition

Previously untreated elderly non-squamous non-small cell lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To determine efficacy and safety of pemetrexed or pemetrexed/bevacizumab for previously untreated elderly non-squamous non-small cell lung cancer and the regimen for phase III study

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

Progression free survival

Key secondary outcomes

Response, Overall survival, Adverse effect, Cost effectiveness


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Pemetrexed

Interventions/Control_2

Pemetrexed plus bevacizumab

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

75 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) histologically confirmed diagnosis of NSqNSCLC; 2) no prior chemotherapy or molecular targeted therapy
3) stage IIIB or IV with no indication of radical radiotherapy, or recurrence after operation
4) no active overlapping cancer
5) age >=75 years
6) Eastern Cooperative Oncology Group (ECOG) performance status (PS)0-1
7) adequate organ function (leukocyte count >=4,000/mm3, hemoglobin level >=9 g/dl, platelet count >=100,000/mm3, ALT and AST levels <100 IU/L,serum bilirubin level =<1.5 mg/dl,serum creatinine level=<1.5 mg/dl,proteinurea =<1+ and PaO2 >=60 Torr (or SpO2 >=90)
8) evaluable lesion
9) informed consent
10) life expectancy greater than 3 months

Key exclusion criteria

1) symptomatic brain metastasis
2) complications as follows: hemoptysis, arterial and venous thromboembolism, uncontrolled hypertension, perforation of the digestive tract/severe fistula/bronchoesophageal fistula, inflammation in abdominal cavity, congenital bleeding predisponency/abnormality of hemostasis, uncontrolled diabetes
3) operation within 28 days
4) planning of thoracic radiotherapy in bevacizumab therapy
5) symptomatic pericardial effusion
6) symptomatic SVC syndrome
7) interstitial pneumonia confirmed in chest X-ray
8) psychotic disease judged should not to participate the trial
9) other inadequacy cases judged by attending physician

Target sample size

82


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yukito Ichinose

Organization

National Kyusyu Cancer Center

Division name

Clinical Research Center

Zip code


Address

3-1-1 Nodame, South, Fukuoka, ZIP811-1395, Japan

TEL

092-541-3231

Email

yichinos@nk-cc.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Minoru Fukuda

Organization

Japanese Red Cross Nagasaki Genbaku Hospital

Division name

Department of Respiratory Diesease

Zip code


Address

3-15 Mori, Nagasaki, 852-8511, Japan

TEL

095-847-1511

Homepage URL


Email

mifukuda258@nifty.com


Sponsor or person

Institute

Lung Oncology Group in Kyushu, Japan (LOGIK)

Institute

Department

Personal name



Funding Source

Organization

Clinical Research Support Center Kyushu

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 08 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 04 Month 01 Day

Date of IRB

2014 Year 04 Month 28 Day

Anticipated trial start date

2012 Year 08 Month 27 Day

Last follow-up date

2017 Year 10 Month 25 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2018 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2012 Year 08 Month 26 Day

Last modified on

2021 Year 02 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010308


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name